Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells

INTRODUCTION: High failure rates of new investigational drugs have impaired the development of breast cancer therapies. One challenge is that excellent activity in preclinical models, such as established cancer cell lines, does not always translate into improved clinical outcomes for patients. New p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gligorich, Keith M, Vaden, Rachel M, Shelton, Dawne N, Wang, Guoying, Matsen, Cindy B, Looper, Ryan E, Sigman, Matthew S, Welm, Bryan E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028696/
https://www.ncbi.nlm.nih.gov/pubmed/23879992
http://dx.doi.org/10.1186/bcr3452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028696/
https://www.ncbi.nlm.nih.gov/pubmed/23879992
http://dx.doi.org/10.1186/bcr3452

Ejemplares similares